FRAMINGHAM, Mass.--(BUSINESS WIRE)--LFB SA, through its rEVO Biologics subsidiary, announced today initiation of the global Phase 3 program for LR769, a novel recombinant form of human Factor VIIa, in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback